Men with 3 of 5 metabolic abnormalities risk diabetes, heart disease

July 14, 2003

DALLAS, July 15 - Men who have at least three metabolic abnormalities are at high risk of developing type 2 diabetes and heart disease, researchers report in today's rapid access issue of Circulation: Journal of the American Heart Association.

Using a new, simplified definition of the "metabolic syndrome"- the clustering of certain metabolic-related heart disease risk factors - researchers predicted diabetes and coronary heart disease (CHD) at an early stage of disease development. This is noteworthy because early prediction might identify people who may benefit from aggressive lifestyle changes such as diet and exercise to delay or derail the disease process, says lead author Naveed Sattar, M.D., an honorary consultant in clinical biochemistry at the Glasgow Royal Infirmary in Scotland.

The new definition of the metabolic syndrome, also known as syndrome X, was developed by the U.S. National Cholesterol Education Panel (NCEP). It incorporates thresholds for five easily measured variables: abdominal obesity, elevated fasting blood triglycerides, low levels of HDL or "good" cholesterol, high fasting blood sugar (glucose) and high blood pressure. A person having any three of the five conditions would be classified as having the syndrome.

A previous definition by the World Health Organization required evidence of insulin resistance - the body's inability to use insulin efficiently - in people with normal glucose tolerance.

"This is a weakness because problems with glucose metabolism usually develop rather late in the syndrome. Glucose intolerance is usually the fourth or fifth condition to appear," Sattar says.

Researchers knew that the metabolic syndrome predisposes people to CHD and diabetes, but little data existed on whether this simpler definition would be as predictive as the older, more stringent criteria.

"This is the first prospective study to show that the new criteria predict excess risk for both CHD and diabetes," he says. Researchers used data from 6,447 men in the West of Scotland Coronary Prevention Study (WOSCOPS) to test the NCEP's recently proposed definition. WOSCOPS is a primary prevention trial that proved the effectiveness of the cholesterol-lowering drug pravastatin for reducing heart disease death and disability. All the men participating in the trial had moderately elevated cholesterol levels. Sattar's group substituted body mass index figures collected in WOSCOPS for abdominal obesity.

Using the new definition, 26 percent of the men had the metabolic syndrome. They had 1.7 times the risk of a CHD event and 3.5 times the risk of developing diabetes during 4.9 years of follow-up, Sattar says. This level of risk was similar to an increase in age of 10 years, or to the risk in smokers.

The risk increased as the number of metabolic abnormalities rose. Men with four or five features of metabolic syndrome had 3.7 times the risk of coronary heart disease and 24.5 times the risk of diabetes compared to those with no abnormalities.

The diabetes finding is particularly striking because currently there are fewer predictive screening charts to identify people at high risk of becoming diabetic than there are for CHD, he says.

Interestingly, the cholesterol-lowering drug seemed equally beneficial for men with and without the metabolic syndrome. It reduced the risk of CHD by 27 percent in those with metabolic syndrome and 31 percent in those without it, he says.

Sattar's group also looked at another variable, the inflammatory marker C-reactive protein (CRP) that other studies have linked to the development of heart disease and diabetes. They found that CRP levels were higher in the men with the metabolic syndrome than in those without it.

Co-authors are Allan Gaw, M.D.; Olga Scherbakova; Ian Ford, Ph.D.; Denis St. J. O'Reilly, M.D.; Steven M. Haffner, M.D.; Chris Isles, M.D.; Peter W. Macfarlane, D.Sc.; Chris J. Packard, D.Sc.; Stuart M. Cobbe, M.D.; and James Shepherd, M.D.
-end-
Editor's note: The American Heart Association's program The Heart Of Diabetes: Understanding Insulin Resistance is a FREE 12-month program that educates people about the association between cardiovascular disease, diabetes and insulin resistance. People may register for the program by calling 1-800-AHA-USA1 or visiting www.americanheart.org/diabetes.

CONTACT: For journal copies only,
please call: 214-706-1396
For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135
Julie Del Barto (broadcast): 214-706-1330

American Heart Association

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.